Belatacept  (Synonyms: BMS 224818; LEA 29Y)

Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation^[1][2]. The component ratio of this product is Active ingredient : Excipients = 1:2.4.

Fusion-CTLA4-IGHG1 Fc

Human

CD80/86^[1]

Belatacept (0-5 mg/mL, 1 h) inhibits T-cell proliferation in a dose-dependent manner^[2].
Belatacept (500 ng/mL, 7 days) enhances predominance of effector-memory T-cells after allogeneic stimulation^[2].
Belatacept (100, 500 ng/mL, 7 days) has no effect on differentiation and allogeneic IFNγ production of isolated effector-memory T cells^[2].
Belatacept (10 μg/mL, 1 h) does not inhibit follicular T Cell-dependent B-Cell differentiation^[4].
Belatacept (40 μg/mL, 10 days) reduces plasmablast differentiation, Ig production, and the major transcription factor Blimp-1 in a T cell-independent manner^[5].
Belatacept (40 μg/mL, 30 min) induces activation of the STAT3 transcription factor in stimulated B cells and reduced the expression of CD86^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Belatacept (intraperitoneal injection, 60 mg/kg) inhibits ABMR (Antibody-Mediated Rejection), and inhibits acute rejection when combined with BTLA (B and T lymphocyte attenuator) overexpression therapy^[3].
Belatacept (intravenous injection, 20 mg/kg) displays immunosuppressive activities in monkeys immunized with sheep red blood cell^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

90 kDa

706808-37-9

Solid

White to off-white

[Belatacept]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Fusion - [CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2 - IGHG1 Fc (Fragment constant)

• [1]. George Melvin, et al. Belatacept: A worthy alternative to cyclosporine?. J Pharmacol Pharmacother. 2012 Jan-Mar; 3(1): 90–92.  [Content Brief]

  [2]. Gretchen N de Graav, et al. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One. 2016 Feb 26;11(2):e0148604.  [Content Brief]

  [3]. Hengcheng Zhang, et al. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation. Front Immunol. 2021 Feb 24;12:618737.  [Content Brief]

  [4]. Gretchen N de Graav, et al. Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Front Immunol. 2017 May 31;8:641.  [Content Brief]

  [5]. laire Leibler, et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. J Am Soc Nephrol. 2018 Mar;29(3):1049-1062.  [Content Brief]

  [6]. Christian P Larsen, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005 Mar;5(3):443-53.  [Content Brief]